Anxiety Disorders
21 cases on anxiolytic selection and management across GAD, panic disorder, social anxiety, specific phobia, and related pediatric and special-population presentations — choose a case below to open its full multi-voice debate.
A newly diagnosed GAD patient names her own priorities — no sexual side effects, no dependence risk — before pharmacology ever enters the room. The debate is whether those priorities are reason enough to start with the less-proven agent.
A newly anxious, newly unemployed patient needs relief faster than an SSRI can provide — and drinks most nights. The debate is whether a fixed, time-limited benzodiazepine bridge is a tool or a risk his own habits make worse.
Approved for anxiety in Europe but never in the United States, pregabalin has genuine trial evidence behind it. A patient who has run out of on-label options tests whether that evidence is enough to justify an off-label, Schedule V prescription.
Two patients with the same new diagnosis face the same SSRI early-activation window very differently — one can absorb it, the other has thirty days before losing her flight certification. The same pharmacology, two different acceptable answers.
A patient convinced his racing heart means something is physically wrong keeps abandoning SSRIs too early to judge them fairly. The debate is whether blunting his physical symptoms with a beta-blocker treats the disorder or just quiets the alarm bell.
Fourteen years of stable function on clonazepam, after two failed SSRI trials, runs into the Beers Criteria's fall and cognitive-risk warnings as a patient turns 65. Real long-term dependence versus function that took fourteen years to build.
A violinist's stage fright and a graduate student's pervasive fear of judgment can both look like "social anxiety" on a chart. The debate is why the same drug that fits one diagnosis has no real mechanism for the other.
Phenelzine has some of the strongest indication-specific evidence any MAOI carries for social anxiety disorder. A patient who has genuinely exhausted three other agents tests whether that evidence justifies the diet and interaction burden that comes with it.
A patient beginning structured exposure therapy for a fear of flying wants medication to get through it. The pharmacology of fear extinction suggests that help might quietly undermine the very learning the therapy depends on.
An NMDA partial agonist with a real mechanistic case for enhancing fear extinction has produced genuinely mixed results across trials. A patient whose exposure-therapy gains aren't holding between sessions tests whether the mechanism is worth trying anyway.
A patient stops her long-stable clonazepam the day her pregnancy test comes back positive, based on something she read online. Three weeks later, the debate is whether an uncertain, likely small teratogenic signal outweighs a documented, worsening relapse.
Eight days into an SSRI trial for GAD, a patient's anxiety feels worse, not better, and he's ready to quit. The debate isn't whether to switch drugs — it's whether he can be kept on this one long enough to find out it was working all along.
Eleven years of stable diazepam runs into a new fall and a new finding on cognitive screening. The debate is no longer whether to taper, but how to do it safely in a 74-year-old living alone.
A patient who has failed five adequate GAD trials asks about ketamine after reading about its use for depression. The debate turns on a label that doesn't cover her at all, and evidence that, while real, isn't nearly as deep as what she read about.
A patient self-treating his anxiety with unmeasured over-the-counter CBD asks if he should just skip prescription medication altogether. The honest answer runs into both a genuinely mixed evidence base and a largely unregulated supplement market.
A seven-year-old hasn't spoken a word at school in a full year, making slow but real progress in behavioral therapy alone. The debate is whether limited pediatric SSRI evidence justifies adding medication to accelerate what therapy is already doing.
A nine-year-old is missing a day of school a week to separation anxiety, with no therapy trial yet attempted. The debate isn't whether CBT belongs first — it's how long to give it before medication earns its place.
A patient responding well to sertraline alone asks whether the CBT referral is still worth his limited time. The evidence for combination treatment is real, but its actual marginal benefit for someone already doing this well is more modest than the general framing suggests.
A patient in stable remission wants to taper off, using a maintenance timeline she read about for depression. The real evidence for anxiety disorders specifically points to a longer window — a distinct teaching point easy to blur.
Three years of well-controlled performance anxiety on propranolol runs into a new asthma diagnosis. The obvious anxiolytic choice now works directly against the patient's own asthma maintenance therapy — a real substitution problem, not a theoretical one.
An 81-year-old who has already failed an SSRI and explicitly refuses dependence risk seems to want exactly what hydroxyzine offers. The real tradeoff is a different risk profile, not a risk-free one, at an age where anticholinergic burden matters just as much as fall risk.